Aug 14, 2023 8:30am EDT FDA Accepts MyMD Pharmaceuticals’ Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA)
Aug 02, 2023 8:30am EDT MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results
Jul 31, 2023 9:00am EDT MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty
Apr 12, 2023 8:30am EDT MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan
Mar 20, 2023 8:55am EDT MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid Arthritis
Mar 08, 2023 8:30am EST MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls
Mar 02, 2023 8:30am EST MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD™ is not a Controlled Substance or Listed Chemical
Feb 28, 2023 8:30am EST MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting
Dec 06, 2022 8:00am EST ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022
